EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

IGF1R Induces ROS Formation in Mitochondria via MICU1 Leads to the Enzalutamide Resistance in Prostate Cancer

Hanlin Li iD, Yutong Chen, Yupeng Zhou, Yang Li, Yukui Gao, Xuanrong Chen, Qianwang Ma, Shimiao Zhu, Simeng Wen

Journal of Cellular and Molecular Medicine · 2026-10 · 30 (20)

DOI: 10.1111/jcmm.71415 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 27.10.2026. Verfasst von Hanlin Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Reactive Oxygen Species, Prostatic Neoplasms, Mitochondria, Drug Resistance, Neoplasm. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

After undergoing ADT treatment, drug resistance has emerged as a major hindrance in the treatment of prostate cancer, with enzalutamide resistance being the most notable. Our objective was to identify a new drug‐resistance mechanism present in post‐ADT‐treatment patients. Utilizing proteomic sequencing, we discovered abnormal increases in IGF1R levels. Subsequent sequencing and bioinformatic analyses showed that IGF1R could cause abnormal changes in the tricarboxylic acid cycle (TCA cycle) and oxidative phosphorylation. This phenomenon may be due to IGF1R's influence on the distribution of mitochondrial Ca 2+ and the production of reactive oxygen species (ROS). Our CHIP and dual‐luciferase experiments confirmed the regulatory relationship between IGF1R and MICU1. The fluorescent results of Ca 2+ and ROS also confirmed that IGF1R could regulate mitochondrial Ca 2+ distribution and ROS production. Our team validated the relationship between IGF1R and drug resistance through cell phenotype experiments, and explored its potential as a therapeutic target through a fa‐ci curve. Finally, we verified the effectiveness of the mechanisms we found through a xenograft assay. Our study confirms the potential for IGF1R as a clinical therapeutic target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Reactive Oxygen SpeciesProstatic NeoplasmsMitochondriaDrug Resistance, NeoplasmPhenylthiohydantoinNitrilesBenzamidesMitochondrial Membrane Transport ProteinsReceptor, IGF Type 1MaleHumansAnimalsCell Line, TumorMiceCalciumXenograft Model Antitumor AssaysGene Expression Regulation, NeoplasticCalcium-Binding ProteinsCation Transport Proteins

Stichwörter der Autor:innen

Ca2+IGF1RROSmetabolismprostate cancer

Substanzen

Reactive Oxygen SpeciesenzalutamidePhenylthiohydantoinNitrilesIGF1R protein, humanBenzamidesMitochondrial Membrane Transport ProteinsMICU1 protein, humanCalciumReceptor, IGF Type 1

Autor:innen und Institutionen

  • Department of Urology, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China.
  • Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.

ORCID-Profile: Hanlin Li

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Li, H., Chen, Y., Zhou, Y., Li, Y., Gao, Y., Chen, X., Ma, Q., Zhu, S., & Wen, S. (2026). IGF1R Induces ROS Formation in Mitochondria via MICU1 Leads to the Enzalutamide Resistance in Prostate Cancer. Journal of Cellular and Molecular Medicine, 30(20). https://doi.org/10.1111/jcmm.71415

Vancouver

Li H, Chen Y, Zhou Y, Li Y, Gao Y, Chen X, et al. IGF1R Induces ROS Formation in Mitochondria via MICU1 Leads to the Enzalutamide Resistance in Prostate Cancer. Journal of Cellular and Molecular Medicine. 2026;30(20). doi:10.1111/jcmm.71415

BibTeX
@article{Li2026,
  author = {Li, Hanlin and Chen, Yutong and Zhou, Yupeng and Li, Yang and Gao, Yukui and Chen, Xuanrong and Ma, Qianwang and Zhu, Shimiao and Wen, Simeng},
  title = {IGF1R Induces ROS Formation in Mitochondria via MICU1 Leads to the Enzalutamide Resistance in Prostate Cancer},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2026},
  volume = {30},
  number = {20},
  doi = {10.1111/jcmm.71415}
}
Kostenlos starten →